CD45RO+ | CD45RA+ | ||||||
---|---|---|---|---|---|---|---|
CD4+ | CD8+ | CD4+ | CD8+ | ||||
Experiment 1 | |||||||
IL-10 release | |||||||
Medium | < Min | < Min | < Min | < Min | |||
T112/3 + SRBC | 1 080 | 14 | < Min | < Min | |||
Proliferation | |||||||
Medium | 211 | 399 | 239 | 546 | |||
T112/3 + SRBC | 18 016 | 3 178 | 1 371 | 503 | |||
Experiment 2 | |||||||
IL-10 release | |||||||
Medium | < Min | < Min | < Min | < Min | |||
T112/3 + SRBC | 1 621 | 156 | < Min | < Min | |||
Proliferation | |||||||
Medium | 113 | 101 | 147 | 123 | |||
T112/3 + SRBC | 11 592 | 17 849 | 4 127 | 131 |
CD45RO+ and CD45RA+ PBL-T were separated into CD4+ and CD8+ subsets, respectively, by negative selection. Cells were activated by CD2 monoclonal antibodies T112 and T113 (1/3000 v/v) in the presence of SRBC (30 μl 5% SRBC for 106cells). Supernatants were harvested after 60 hours and the IL-10 content of each (results expressed in pg/ml; detection limit (min) 10 pg/ml) was determined by using ELISA. Cell growth was measured by the incorporation of [3H]-thymidine after four days. Results are expressed as the mean cpm of triplicate cultures. SD < 20%.